To include your compound in the COVID-19 Resource Center, submit it here.

Elan sells Abelcet rights to Enzon

ELN agreed to sell ENZN North American and Japanese rights for its Abelcet antifungal for $370 million in cash. ELN retains rights to market

Read the full 242 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE